Medtide Inc

Medtide Inc. operates as a contract research, development, and manufacturing organization (CRDMO), providing comprehensive services across the entire pharmaceutical lifecycle, from initial drug discovery and preclinical investigation through to clinical development and commercial-scale production. The company specializes in the synthesis of novel peptide chemical entities for discovery purposes, along with the development of peptide-based chemistry, manufacturing, and control (CMC) processes, and their subsequent commercial manufacturing. A core area of its developmental focus is on glucagon-like peptide-1 (GLP-1) molecules, which it designs for both oral and/or injectable administration. Medtide leverages a suite of proprietary research and development platforms, including OmniPeptSynth, PeptiConjuX, PeptiNuclide LinkTech, GreenSynth Innovations, and Impurity Screening. Its client base spans multiple regions globally, including China, the United States, Japan, Europe, South Korea, and Australia. Established in 2020 as Taide Pharmaceutical (Zhejiang) Co., Ltd, the company rebranded to Medtide Inc. in February 2023 and maintains its headquarters in Hangzhou, China.